Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's AKEEGA (niraparib and abiraterone acetate) receives European Commission approval for BRCA1/2-mutated metastatic hormone-sensitive prostate cancer
Small molecule combination therapy, cancer, PARP inhibitor, prostate cancer, BRCA mutations, precision medicine - Read more

Alfasigma, GSK strike $690M deal for linerixibat itching treatment awaiting FDA approval
Licensing deal, rare disease, small molecule, milestone payments, commercialization - Read more

Tenacia Biotechnology, Rapport Therapeutics partner on epilepsy drug RAP-219 for China, $308M milestones
Licensing deal, neurological, small molecule, milestone payments - Read more

Novo Nordisk, Hims & Hers partner to sell GLP-1 drugs Ozempic and Wegovy, ending lawsuit dispute
Commercialization agreement, diabetes/obesity, digital health, settlement agreement - Read more

kyron.bio, Servier partner on precision glycoengineering for antibody therapeutics, financial terms undisclosed
Research collaboration, antibody, drug discovery, milestone payments - Read more

Zelluna, Etcembly collaborate on AI-enabled TCR engineering targeting KKLC1 for solid cancer therapies
Research collaboration, oncology, AI/ML, cell therapy - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

Regeneron Pharmaceuticals reports positive Ph3 data for olatorepatide (olatorepatide) targeting GLP-1/GIP receptors for obesity treatment
Protein therapy, metabolic, GLP-1/GIP receptor agonist, obesity, combination therapy - Read more

Pfizer's tilrekimig (PF-07275315) hits Ph2 endpoints in moderate-to-severe atopic dermatitis targeting IL-4/IL-13/TSLP pathways
Antibody, autoimmune, trispecific antibody, atopic dermatitis, IL-4/IL-13/TSLP targets - Read more

Xenon Pharmaceuticals' azetukalner exceeds Ph3 expectations for focal onset seizures, plans FDA filing
Small molecule, neurological, potassium channel opener, epilepsy, focal onset seizures, Kv7 channel - Read more

AbbVie's ABBV-295 shows competitive weight loss results targeting amylin pathway in obesity Ph1 trial
Small molecule, metabolic, amylin analog, obesity, weight loss - Read more

Bristol Myers Squibb's mezigdomide hits Ph3 goals for relapsed or refractory multiple myeloma treatment
Protein therapy, cancer, protein degrader, multiple myeloma, combination therapy - Read more

Vertex Pharmaceuticals' povetacicept meets Ph3 endpoints for IgA nephropathy, eyes accelerated FDA approval
Protein therapy, autoimmune, dual BAFF/APRIL inhibitor, IgA nephropathy, proteinuria reduction - Read more

Tacit Therapeutics launches with $19M funding to develop RNA editing therapies for neurological diseases
RNA editing, neurological, strategic, major transaction - Read more [Paywall]

Relmada Therapeutics raises $160M private placement, advancing oncology and CNS therapies
Clinical-stage, oncology, neurological, central nervous system - Read more

FDA's Prasad departure boosts rare disease biotechs uniQure, Replimune, Disc Medicine stock prices premarket Monday
Gene therapy, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA rejects Incyte's Zynyz (retifanlimab) label expansion for non-small cell lung cancer due to manufacturing issues
Monoclonal antibody, cancer, anti-PD-1, non-small cell lung cancer - Read more

Roche's giredestrant (selective estrogen receptor degrader) fails Ph3 trial for first-line metastatic breast cancer treatment
Small molecule, cancer, selective estrogen receptor degrader, breast cancer, combination therapy - Read more

Astellas and Hovon's Xospata (gilteritinib) fails Ph3 primary endpoint for newly diagnosed FLT3-mutated acute myeloid leukemia
Small molecule, cancer, FLT3 inhibitor, acute myeloid leukemia, gilteritinib - Read more

Ipsen voluntarily withdraws cancer drug Tazverik from market due to secondary malignancy risks in clinical trial
Small molecule, oncology, strategic, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here